Cargando…

Eubacterium rectale Improves the Efficacy of Anti-PD1 Immunotherapy in Melanoma via l-Serine-Mediated NK Cell Activation

Natural killer (NK) cells, as key immune cells, play essential roles in tumor cell immune escape and immunotherapy. Accumulating evidence has demonstrated that the gut microbiota community affects the efficacy of anti-PD1 immunotherapy and that remodeling the gut microbiota is a promising strategy t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Nian, Chen, Lihui, Yan, Mingjie, Tao, Qian, Wu, Jie, Chen, Jing, Chen, Xiang, Zhang, Wei, Peng, Cong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AAAS 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202379/ https://www.ncbi.nlm.nih.gov/pubmed/37223471 http://dx.doi.org/10.34133/research.0127

Ejemplares similares

Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1
por: Liu, Nian, et al.
Publicado: (2023)

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
por: Liu, Nian, et al.
Publicado: (2023)

Eubacterium rectale contributes to colorectal cancer initiation via promoting colitis
por: Wang, Yijia, et al.
Publicado: (2021)

Lower gut abundance of Eubacterium rectale is linked to COVID-19 mortality
por: Liu, Yingzhi, et al.
Publicado: (2023)

Eubacterium rectale Attenuates HSV-1 Induced Systemic Inflammation in Mice by Inhibiting CD83
por: Islam, S. M. Shamsul, et al.
Publicado: (2021)

A mathematical model of Bacteroides thetaiotaomicron, Methanobrevibacter smithii, and Eubacterium rectale interactions in the human gut
por: Adrian, Melissa A., et al.
Publicado: (2023)

Gut Microbiota Eubacterium callanderi Exerts Anti-Colorectal Cancer Activity
por: Ryu, Seoung Woo, et al.
Publicado: (2022)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Genome-Based Reclassification of Strain KIST612, Previously Classified as Eubacterium limosum, into a New Strain of Eubacterium callanderi
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Antitumor Activity and Its Properties of Eubacterium lentum
por: Morinaga, Shinich, et al.
Publicado: (1988)

The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun
por: Yu, Pian, et al.
Publicado: (2022)

Analysis of 1321 Eubacterium rectale genomes from metagenomes uncovers complex phylogeographic population structure and subspecies functional adaptations
por: Karcher, Nicolai, et al.
Publicado: (2020)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Identification of a Mammalian-type Phosphatidylglycerophosphate Phosphatase in the Eubacterium Rhodopirellula baltica
por: Teh, Phildrich G., et al.
Publicado: (2013)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Comparison of arthritogenic and nonarthritogenic Eubacterium aerofaciens cell walls
por: Zhang, X, et al.
Publicado: (2001)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Flavonifractor (Eubacterium) plautii bloodstream infection following acute cholecystitis
por: Berger, Fabian K., et al.
Publicado: (2018)

Butyrate Levels in the Transition from an Infant- to an Adult-Like Gut Microbiota Correlate with Bacterial Networks Associated with Eubacterium Rectale and Ruminococcus Gnavus
por: Nilsen, Morten, et al.
Publicado: (2020)

An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
por: Machiraju, Devayani, et al.
Publicado: (2021)

Complete Genome Sequence of Eubacterium hallii Strain L2-7
por: Shetty, Sudarshan A., et al.
Publicado: (2017)

Adaptive Laboratory Evolution of Eubacterium limosum ATCC 8486 on Carbon Monoxide
por: Kang, Seulgi, et al.
Publicado: (2020)

High methanol‐to‐formate ratios induce butanol production in Eubacterium limosum
por: Wood, Jamin C., et al.
Publicado: (2021)

Butyrate production in the acetogen Eubacterium limosum is dependent on the carbon and energy source
por: Litty, Dennis, et al.
Publicado: (2021)

Expanding the genetic engineering toolbox for the metabolically flexible acetogen Eubacterium limosum
por: Sanford, Patrick A, et al.
Publicado: (2022)

Curcumin analog GO‐Y030 boosts the efficacy of anti‐PD‐1 cancer immunotherapy
por: MaruYama, Takashi, et al.
Publicado: (2021)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
por: Gao, Yang, et al.
Publicado: (2020)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
por: Flaus, A., et al.
Publicado: (2021)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b2k7ccdbe57e70f6rtn5ulfm20